Neumora Therapeutics reported second quarter 2026 financial results and announced a leadership transition effective August 14, 2026. Joshua Pinto, Ph.D., succeeded Paul L. Berns as Chief Executive Officer and was appointed to the Board of Directors; Mr. Berns became Executive Chairperson. Doron Sagman, M.D., FRCPC, was appointed Chief Medical Officer. For the quarter ended June 30, 2026, the company reported a net loss of $43.1 million, compared to $52.7 million in the prior year period. Research and development expenses decreased to $29.3 million from $38.7 million, while general and administrative expenses fell to $12.9 million from $15.3 million. The company held $116.8 million in cash and cash equivalents as of June 30, 2026, which is expected to fund operations into the third quarter of 2027. Neumora Therapeutics operates in the biopharmaceutical industry, developing clinical-stage treatments for brain diseases.

Neumora Therapeutics, Inc. reported favorable pre-clinical toxicology results for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease. Following a for-cause audit that cleared discrepancies in a previous study, a repeat 13-week rat toxicology study in 162 animals showed no unexpected in-life adverse findings. The company plans to submit an IND application in the fourth quarter of 2026 and initiate a Phase 1 study by the end of 2026. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for brain diseases and underserved, prevalent diseases.

Neumora Therapeutics is discontinuing development of navacaprant after Phase 3 KOASTAL-2 and KOASTAL-3 studies for major depressive disorder failed to achieve statistical significance on primary and key secondary endpoints. Consequently, the company implemented a 35% reduction in force, expected to yield $10 million in annualized savings against $2 million in one-time restructuring costs. Neumora also entered a Third Amendment to its Loan and Security Agreement with K2 HealthVentures LLC, which extends the interest-only period and modifies minimum liquidity covenants effective July 1, 2026. Following these changes, the company expects its cash runway to extend into the third quarter of 2027. Neumora Therapeutics is a biotechnology company focused on developing neuroscience-based medicines.